Lantheus (LNTH) to Release Quarterly Earnings on Thursday

Lantheus (NASDAQ:LNTH) is expected to release its earnings data before the market opens on Thursday, February 27th. Analysts expect Lantheus to post earnings of $1.57 per share and revenue of $376.61 million for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Lantheus Price Performance

Shares of LNTH stock opened at $80.07 on Wednesday. Lantheus has a 1-year low of $56.44 and a 1-year high of $126.89. The stock’s 50-day moving average is $89.77 and its 200 day moving average is $96.81. The company has a market cap of $5.57 billion, a P/E ratio of 13.32 and a beta of 0.44.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on LNTH. Truist Financial reissued a “buy” rating and issued a $120.00 price target (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. The Goldman Sachs Group began coverage on Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price for the company. Finally, StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $131.86.

Insider Activity

In related news, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.